Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
29 6월 2023 - 10:00PM
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the
appointment of Sasha Damouni Ellis as Executive Vice President and
Chief Corporate Affairs Officer, effective July 10, 2023. Ms.
Damouni Ellis will be responsible for the Company’s strategic
approach to corporate communications, government affairs, investor
relations and patient advocacy, as well as for establishing Vir’s
corporate social responsibility and environmental, social and
governance efforts. She will report to Vir’s Chief Executive
Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the
Company’s Executive Management Team.
“Sasha has an impressive track record as both a
corporate communications and investor relations leader. Her
insights and expertise will be invaluable to our executive team as
we continue advancing our robust pipeline of innovative therapies
aimed at the treatment of infectious diseases,” said Dr. De
Backer.
“I’m honored to join Vir, a company with a
strong clinical pipeline and an exciting future ahead targeting
significant unmet medical needs around the world,” said Ms. Damouni
Ellis. “I look forward to working with Marianne and the exceptional
team and Board of Directors at Vir who have established a
successful track record of scientific innovation, commitment to
patients and a strong employee culture.”
Ms. Damouni Ellis joins Vir from Marinus
Pharmaceuticals, where she served as Senior Vice President,
Corporate Affairs and Investor Relations. Previously, she was
Director of External Communications and Media Relations for Bayer
U.S., where she drove external brand-building strategies in
therapeutic areas of oncology, hemophilia, cardio-pulmonary, and
women’s health. Earlier in her career, Ms. Damouni Ellis was a
Senior Healthcare Journalist at Bloomberg News and Global Editor of
BioPharm Insight, formerly a division of the Financial Times Group,
which she launched in New York and London.
She earned her Master of Arts from City,
University of London’s Graduate School of Journalism, in the United
Kingdom, and her Bachelor of Arts Degree from Richmond, the
American International University in London, United Kingdom.
About Vir BiotechnologyVir
Biotechnology is a commercial-stage immunology company focused on
combining immunologic insights with cutting-edge technologies to
treat and prevent serious infectious diseases. Vir has assembled
four technology platforms that are designed to stimulate and
enhance the immune system by exploiting critical observations of
natural immune processes. Its current development pipeline consists
of product candidates targeting COVID-19, hepatitis B and D
viruses, influenza A and human immunodeficiency virus. Vir
routinely posts information that may be important to investors on
its website.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,”
“anticipate,” “promising” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Vir’s expectations
and assumptions as of the date of this press release.
Forward-looking statements contained in this press release include,
but are not limited to, statements regarding Vir’s strategy and
plans; and the potential of, and expectations for, Vir’s clinical
pipeline. Many important factors may cause differences between
current expectations and actual results, including unexpected
safety or efficacy data or results observed during clinical trials
or in data readouts; the timing and outcome of Vir’s planned
interactions with regulatory authorities; difficulties in obtaining
regulatory approval; uncertainty as to whether the anticipated
benefits of Vir’s collaborations with other companies can be
achieved; difficulties in collaborating with other companies;
challenges in accessing manufacturing capacity; clinical site
activation rates or clinical trial enrollment rates that are lower
than expected; successful development and/or commercialization of
alternative product candidates by Vir’s competitors; changes in
expected or existing competition; delays in or disruptions to Vir’s
business or clinical trials due to the COVID-19 pandemic,
geopolitical changes or other external factors; and unexpected
litigation or other disputes. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from
later-stage or larger-scale clinical trials and do not ensure
regulatory approval. You should not place undue reliance on these
statements, or the scientific data presented. Other factors that
may cause actual results to differ from those expressed or implied
in the forward-looking statements in this press release are
discussed in Vir’s filings with the U.S. Securities and Exchange
Commission, including the section titled “Risk Factors” contained
therein. Except as required by law, Vir assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Contact:
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1-314-368-5189
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Vir Biotechnology (NASDAQ:VIR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024